(OSUR) OraSure Technologies, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(OSUR) OraSure Technologies, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This OraSure Technologies, Inc. BCG Matrix gives a clear view of how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs, supporting strategy and portfolio decisions. This page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
OraQuick HIV Self-Test
OraQuick HIV Self-Test is a Star in OraSure Technologies, Inc.'s BCG Matrix because it is the first FDA-approved oral-fluid HIV test and the clearest growth brand in diagnostics. The self-test format supports home use, gives results in about 20 minutes, and expands access for people who avoid clinic testing. It fits a high-growth, high-share role with strong public-health reach.
Oragene DNA Collection Kits
Oragene DNA Collection Kits are a core DNA Genotek brand and fit a Star in OraSure Technologies, Inc.'s BCG Matrix because they support research, ancestry, and disease-risk workflows in a market with broad genomics adoption. The line is sold in more than 100 countries, giving it wide reach and strong use across labs and direct-to-consumer testing. As saliva-based DNA testing scales, Oragene stays well placed for growth and share gains.
ORAcollect Saliva DNA Kits
ORAcollect Saliva DNA Kits support saliva collection for molecular and genomic testing, and their use in PCR and sequencing keeps demand tied to active research and commercial workflows. The kit complements OraSure’s Oragene line across both channels, helping the Company defend share in noninvasive sample collection. With sustained pull from genomic testing, ORAcollect fits Star status in the BCG Matrix.
OMNIgene Molecular Stabilization Products
OMNIgene Molecular Stabilization Products fit a "Question Mark" in OraSure Technologies, Inc.'s BCG Matrix: they support decentralized molecular testing by preserving sample quality before lab analysis, which matters in home collection, clinics, and research workflows.
Growth should track broader adoption of pre-analytics and molecular collection, especially as testing moves closer to the patient and sample integrity becomes a bigger issue.
- Stabilizes samples for molecular testing
- Used in decentralized diagnostics
- Benefits from pre-analytics adoption
Microbiome Collection Solutions
Microbiome Collection Solutions fit OraSure Technologies, Inc.’s Stars profile: demand keeps rising in academic and commercial microbiome work, and the company sells niche collection tools that sit early in the workflow. The global microbiome research market is still expanding fast, so this line can scale as more labs standardize sample collection.
- High-growth, specialized niche
- Supports recurring research use
- Low-share, high-upside category
OraQuick and Saliva Tests Lead the Growth Surge
OraQuick HIV Self-Test is the clearest Star: FDA-approved, home use, and about 20-minute results support high-growth demand. Oragene DNA, ORAcollect, and OMNIgene also fit Star or near-Star roles because saliva and molecular collection are scaling fast across more than 100 countries and decentralized testing.
| Product | Star role | Key driver |
|---|---|---|
| OraQuick HIV Self-Test | Star | Home HIV testing |
| Oragene DNA | Star | 100+ countries |
| ORAcollect | Star | Saliva DNA use |
What is included in the product
Detailed Word Document
OraSure’s BCG Matrix maps its diagnostics portfolio to spot Stars, Cash Cows, Question Marks, and Dogs for invest/hold/divest decisions.
Editable Excel File
Quick BCG snapshot of OraSure Technologies, Inc. to pinpoint strengths, drags, and action priorities fast.
Reference Sources
OraSure Technologies, Inc. Reference Sources provide a credible trail that backs key claims and speeds confident decision-making.
Cash Cows
OraQuick Professional HIV Rapid Tests
OraQuick Professional HIV Rapid Tests sit in a mature, recurring market, so demand is steady rather than fast-growing. OraSure Technologies, Inc. has a long-standing brand and broad clinic and public-health distribution, which supports repeat orders and predictable cash flow. In BCG terms, this is a classic Cash Cow: low-growth, but strong in generating cash for the rest of the portfolio.
OraSure Oral Fluid Collection Device
OraSure Oral Fluid Collection Device is a legacy HIV antibody screening and confirmation platform, so demand stays steady in established testing workflows. Growth is limited in FY2025, but the installed base supports repeat use and healthier margins. In BCG terms, it fits Cash Cow: low growth, strong cash generation.
Intercept Drug Testing Systems
Workplace and forensic drug testing is a mature, low-growth market, and Intercept has long-standing use with labs and employers, so it fits a classic Cash Cow profile. Its value comes from repeat volume and entrenched workflows, not fast category growth.
For OraSure Technologies, Inc., that means steady cash generation with limited need for heavy reinvestment, which is exactly what a BCG Cash Cow should do.
Q.E.D. Saliva Alcohol Test
Q.E.D. Saliva Alcohol Test sits in a small, steady niche with limited growth upside, so it fits the Cash Cow box in OraSure Technologies, Inc.'s BCG Matrix. The product is mature, needs little new investment, and can keep producing cash from an established customer base. That is a classic milk-the-cash asset.
- Mature product
- Low expansion needs
- Stable niche demand
- Cash-generating profile
OraQuick HCV Rapid Antibody Test
OraQuick HCV Rapid Antibody Test sits in a Cash Cow spot because hepatitis C screening is a mature, routine diagnostic category, used in clinics, hospitals, and public-health screening. Demand is steady, but it is not a big growth driver for OraSure Technologies, Inc. as HCV testing is largely tied to ongoing screening needs, not rapid market expansion.
Its value is in reliable, recurring use rather than sharp volume growth, which fits the BCG Cash Cow profile well.
- Established HCV screening category
- Routine clinical and public-health use
- Stable demand, limited growth upside
OraSure’s Cash Cows Deliver Steady, Repeatable Cash Flow
OraSure Technologies, Inc.'s Cash Cows are mature, low-growth products with repeat demand and steady cash flow. OraQuick Professional HIV Rapid Tests, the Oral Fluid Collection Device, Intercept, Q.E.D. Saliva Alcohol Test, and OraQuick HCV Rapid Antibody Test all rely on established workflows, so they need limited reinvestment and help fund newer bets.
| Product | BCG | Profile |
|---|---|---|
| OraQuick Professional HIV Rapid Tests | Cash Cow | Stable clinic demand |
| Intercept | Cash Cow | Mature drug testing |
Get Your Copy
OraSure Technologies, Inc. Reference Sources
The OraSure Technologies, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content or hidden changes—just the full, ready-to-use report. Download it instantly and use it for strategy, analysis, or presentations. What you preview is what you get.
Dogs
InteliSwab COVID-19 Rapid Tests
InteliSwab COVID-19 Rapid Tests sit in the Dogs quadrant: demand for COVID antigen tests fell hard after peak pandemic use, and the product was built on a one-time public-health surge. That leaves OraSure Technologies, Inc. with low growth and weak long-term share in this line. In BCG terms, it is a cash drag unless costs stay tightly managed.
OraQuick Ebola Rapid Antigen Test
OraSure Technologies, Inc.'s OraQuick Ebola Rapid Antigen Test sits in Dog territory because Ebola demand is outbreak-driven, not recurring. The market is geographically narrow, with testing needed only in specific outbreak zones, so commercial scale stays small and uneven.
That means revenue is hard to sustain across 2025-2026, even if the test matters in a crisis. For BCG purposes, it has low share and low growth, so capital should stay focused on higher-volume platforms.
Legacy Immunoassay Tests and Reagents
Legacy Immunoassay Tests and Reagents remain a mature, low-growth line for OraSure Technologies, Inc. In fiscal 2025, these legacy diagnostics faced heavy pricing pressure and limited product differentiation, which kept margins and share modest. That makes this Dogs segment a weak cash user with little clear path to strong growth.
COVID-19 Molecular Collection Devices
COVID-19 Molecular Collection Devices were built for pandemic-era testing demand, but that surge has normalized and the category now shows weak growth. For OraSure Technologies, Inc., this makes the segment more of a Dogs asset in the BCG Matrix: low market momentum and limited upside.
- Demand was pandemic-led, not structural.
- Growth has cooled as testing eased.
- Low momentum fits a Dogs profile.
Pandemic-Response Test Inventory
Pandemic-Response Test Inventory is a Dog for OraSure Technologies, Inc. because emergency-response diagnostics swing with outbreaks and public health events, not steady end-user demand. That makes revenue visibility weak and working capital less efficient; even a 10x surge in one crisis can fade fast when the event ends. In BCG terms, it has low strategic value and looks like a low-share, low-growth hold.
- Event-driven demand
- Weak repeat adoption
- Low revenue visibility
- Low strategic value
OraSure’s Dog Assets Face Weak 2025-2026 Demand
OraSure Technologies, Inc.'s Dogs are mostly pandemic or outbreak tied, so 2025-2026 demand stays weak. InteliSwab, COVID-19 molecular devices, and pandemic inventory all face low growth and low share as test use normalizes. Legacy immunoassays and OraQuick Ebola are also mature or event driven, so they look like cash drags unless tightly managed.
| Dog asset | Why it fits |
|---|---|
| InteliSwab | COVID demand faded |
| OraQuick Ebola | Outbreak only |
| Legacy tests | Low growth |
Question Marks
GenoFIND Genomics Laboratory Services
GenoFIND sits in the Question Mark box: genomics testing demand keeps rising, but OraSure Technologies, Inc. has a much smaller service footprint than lab giants like Labcorp and Quest, which each operate at multi-billion-dollar scale. That means the unit has growth potential, but its share is still uncertain and it needs capital, customers, and proof it can compete.
Colli-Pee Volumetric Urine Collection Device
Colli-Pee fits Question Marks: first-void urine sampling is still niche, but it is gaining use in biomarker and infectious-disease testing. OraSure Technologies does not break out Colli-Pee revenue, so its 2025/2026 share base still looks small. Adoption is promising, but it has not yet shown the scale needed to move beyond a high-upside, low-share play.
RNA Collection Products
RNA collection products sit in a growing RNA workflow market, and OraSure Technologies, Inc. sells tools that support diagnostics and research use cases. In 2025, the category still looked early-stage for OraSure, with demand expanding but share not yet clearly dominant. That makes it a classic Question Mark: good growth, but limited scale.
Animal Testing Collection Kits
Animal Testing Collection Kits fit OraSure Technologies, Inc. as a Question Mark: preclinical and veterinary labs need better sample preservation, and OraSure has products in that niche, but the market is still split across many small players. The upside is real, yet unproven because no clear scale leader has emerged.
- Demand is tied to sample integrity.
- Fragmentation keeps share gains uncertain.
- Growth path needs proof of scale.
Commercial Ancestry and Lifestyle Sample Kits
Consumer genomics still has growth pockets in 2025, led by ancestry and wellness use cases, but OraSure Technologies, Inc. mostly supplies sample-collection kits, not the end customer. That keeps current share low, yet it gives OraSure a real option if a partner scales, since kit volumes can rise without heavy brand spend. One recent read on the market is that the category remains niche but durable, with demand tied to repeat testing and at-home convenience.
- Low share, but usable growth option
- Partner-led, not direct-to-consumer
- Best tied to ancestry and wellness
OraSure’s Growth Bets Remain Question Marks, Not Cash Engines
GenoFIND, Colli-Pee, RNA collection, and animal testing kits remain Question Marks for OraSure Technologies, Inc.: each sits in a growing niche, but none has disclosed 2025/2026 scale or clear market share strong enough to lead yet.
That makes them upside plays, not cash engines, because demand is real but adoption is still uneven and fragmented.
| Unit | BCG view | 2025/2026 signal |
|---|---|---|
| GenoFIND | Question Mark | Small footprint, growth optionality |
| Colli-Pee | Question Mark | Niche, early adoption |
| RNA collection | Question Mark | Early-stage demand |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.